Pasar al contenido principal
U.S. flag

Un sitio oficial del Gobierno de Estados Unidos

Así es como usted puede verificarlo

Dot gov
Los sitios web oficiales usan .gov
Un sitio web .gov pertenece a una organización oficial del Gobierno de Estados Unidos.
Https

Los sitios web seguros .gov usan HTTPS
Un candado ( Candado Un candado cerrado ) o https:// significa que usted se conectó de forma segura a un sitio web .gov. Comparta información sensible sólo en sitios web oficiales y seguros.

  • Quiénes somos
    • Sobre la DEA
    • Mission
    • Nuestra historia
    • Divisiones Nacionales
      • Atlanta
        • Atlanta Leadership
        • Atlanta Contacts
      • Caribbean
        • Caribbean Leadership
        • Caribbean Contacts
      • Chicago
        • Chicago Leadership
        • Chicago Contacts
      • Dallas
        • Dallas Leadership
        • Dallas Contacts
      • Detroit
        • Detroit Leadership
        • Detroit Contacts
      • El Paso
        • El Paso Leadership
        • El Paso Contacts
      • Headquarters
      • Houston
        • Houston Leadership
        • Houston Contacts
      • Los Angeles
        • Los Angeles Leadership
        • Los Angeles Contacts
      • Louisville
        • Louisville Leadership
        • Louisville Contacts
      • Miami
        • Miami Leadership
        • Miami Contacts
      • New England
        • New England Leadership
        • New England Contacts
      • New Jersey
        • New Jersey Contacts
      • New Orleans
        • New Orleans Leadership
        • New Orleans Contacts
      • New York
        • New York Leadership
        • New York Contacts
      • Omaha
        • Omaha Leadership
        • Omaha Contacts
      • Philadelphia
        • Philadelphia Leadership
        • Philadelphia Contacts
      • Phoenix
        • Phoenix Leadership
        • Phoenix Contacts
      • Rocky Mountain
        • Rocky Mountain Contacts
      • San Diego
        • San Diego Leadership
        • San Diego Contacts
      • San Francisco
        • San Francisco Contacts
      • Seattle
        • Seattle Contacts
      • St. Louis
        • St. Louis Leadership
        • St. Louis Contacts
      • Washington, DC
        • Washington Leadership
        • Washington Contacts
    • DEA Museum
    • Oficinas extranjeras
      • Africa
      • Andean
      • Caribbean
      • Europe
      • Far East
      • Middle East
      • North and Central America
      • Southern Cone
    • Divisiones operativas
      • División de Aviación
      • División de Control de Desvíos
    • Wall of Honor
    • Contáctenos
      • Submit a Tip
      • Extortion Scam
      • Public Affairs
      • Social Media Directory
  • Lo que hacemos
    • Orden público
      • DEA Office of Training
        • Office of Training Programs
      • El Paso Intelligence Center (EPIC)
        • Leadership
        • Mission
        • Services
        • Contacts
      • Forensic Sciences
        • Computer Forensics Program
        • Environmental Management
        • Laboratories
      • Intelligence
      • Operations
        • Administrative Law Judges
        • DEA Asset Forfeiture
        • Domestic Cannabis Suppression / Eradication Program
        • HIDTA
        • OCDETF
        • State and Local Task Forces
    • Educación y prevención
      • DEA’s Family Summit
      • Operation Engage
      • Community Outreach
      • Red Ribbon
        • Kiki and the History of Red Ribbon Week
        • Red Ribbon Toolkit - Resources For Your Community
      • Just Think Twice
      • Campus Drug Prevention
      • Get Smart About Drugs
      • Operation Prevention
    • Información sobre las drogas
      • Drug Policy
      • Drug Scheduling
      • The Controlled Substances Act
    • News
      • Alerts
      • Press Releases
      • Most Wanted Fugitives
        • All Fugitives
      • Stories
      • Events
      • Speeches
      • Testimony
    • Campaigns
      • One Pill Can Kill
        • Partner Toolbox
        • Social Media Campaign
      • DEA National Prescription Drug Take Back Day
  • Carreras
    • Agentes especiales
      • Preguntas frecuentes de los agentes especiales
      • Anuncios de empleo para agentes especiales
    • Investigador de desvíos
      • Diversion Investigator Job Announcement
    • Especialista en investigación de inteligencia
      • Anuncios de trabajo de especialista en investigación de inteligencia
      • Preguntas frecuentes de los especialistas en investigación de inteligencia
      • Autoridad de contratación de la Categoría A: Especialista en investigación de inteligencia
    • Carreras de ciencias forenses
    • Carreras profesionales y administrativas
    • Carreras para estudiantes y de nivel básico
    • Cómo aplicar
      • Empleador con igualdad de oportunidades
      • Requisitos de empleo
      • Cómo reclamar la preferencia de los veteranos
      • Consideración prioritaria
      • Beneficios
      • Veteranos y personas con discapacidades
  • Recursos
    • Recovery Resources
    • Data and Statistics
      • Domestic Arrests
      • Staffing and Budget
    • Ley de Libertad de Información
      • About FOIA
      • Contact DEA FOIA
      • Make a Request
      • What Happens After Making a Request
      • Requester Categories
      • Fees Charged
      • Fee Waiver
      • FOIA FAQ
      • FOIA Logs and Reports
      • FOIA Library
      • Additional FOIA Links
      • FOIA Exemptions
      • What Are Exclusions?
      • Privacy Act
      • Privacy Act Exemptions
      • Privacy Impact Assessment and Management Information Systems
    • Publications
    • Galerías Multimedia
    • Programa de Asistencia a Testigos para Víctimas
      • Victim Witness Assistance Program Resources

United States Drug Enforcement Administration

  • Buscar
  • Menú Completo

Main Menu

  • Quiénes somos
  • Lo que hacemos
  • Carreras
  • Recursos
  • Recibir Actualizaciones
  • Scam Alert
  • English
  • ES

PUBLIC SAFETY ALERT

DEA Reports Widespread Threat of Fentanyl Mixed with Xylazine - DEA Reports Widespread Threat of Fentanyl Mixed with Xylazine

Drug Enforcement Administration

Jacob D. Galvan, Acting Special Agent in Charge
Seattle
@DEASeattleDiv
Abril 25, 2022
Contact:
Phone Number: (571) 387-3831
For Immediate Release

Two Naturopaths Agree to Pay $32,000 in Civil Penalties For Improper Prescription of Opioids and Controlled Substances

SPOKANE, Wash.– Dr. Jacqueline Thomas, N.D., an East Wenatchee-based naturopathic doctor, and Dr. Rebecka Hoppins, an Edmonds-based naturopathic doctor, have each agreed to pay $16,500 to resolve allegations under the Controlled Substances Act that they improperly prescribed controlled substances.  The Controlled Substances Act regulates certain drugs deemed to pose a risk of abuse and dependence.  To protect public safety and prevent misuse and diversion, the Act requires practitioners to register with the Drug Enforcement Administration (“DEA”) to prescribe these controlled substances.  

During the relevant time period, Dr. Thomas and Dr. Hoppins were both naturopathic doctors licensed and practicing in the State of Washington.  Under state and federal law, as naturopathic doctor, Dr. Thomas and Dr. Hoppins were only authorized to prescribe two types of controlled substances: codeine and testosterone products.  Nonetheless, in the settlement agreement between the United States and Dr. Thomas, Dr. Thomas admitted to issuing 110 prescriptions for controlled substances that she was not licensed to prescribe between December 2016 and September 2021. These included the narcotic opioid tramadol; the sleep aids zolpidem (often sold under the brand name Ambien) and eszopiclone (often sold under the brand name Lunesta); the sedative pregabalin (sometimes sold under the brand name Lyrica); and the diet drug phentermine. Similarly, in the settlement agreement between Dr. Hoppins and the United States, Dr. Hoppins admitted to issuing 110 invalid prescriptions for controlled substances between 2017 and 2022, including the benzodiazepine alprazolam; the narcotic opioids hydrocodone and tramadol; and the sleep aids eszopiclone (commonly prescribed under the brand name Lunesta) and zopidem (often sold under the brand name Ambien).

The settlement agreement also further sets forth that both doctors ceased their improper prescribing practices after being contacted by the DEA.  Dr. Hoppins voluntarily surrendered her DEA registration and implemented additional controls to ensure appropriate prescribing going forward, while Dr. Thomas entered into a separate compliance agreement with DEA to submit regular prescribing logs and to undertake additional corrective actions to ensure that this conduct does not recur. 

“The careless and irresponsible prescribing habits of Dr. Hoppins and Dr. Thomas are a violation of federal law and in serious breach of their naturopathic license, presenting a clear and present danger to our nation’s health, safety and security,” said Frank A. Tarentino III, Special Agent in Charge, DEA Seattle Field Division.  “Although regretful and conciliatory, the behavior of these medical professionals significantly contributes to the many complexities fueling the opioid epidemic and endangering the citizens of Washington. We will continue to work with our local, state and federal law enforcement partners in the opioid and overdose prevention awareness campaign and relentless pursuit of all those involved in the trafficking of opioids.”

 “I am relieved that it does not appear anyone was seriously harmed by medications improperly prescribed by these practitioners, and I commend both for admitting their past conduct and committing to strict compliance going forward. But when a healthcare practitioner prescribes controlled substances that she is not licensed or qualified to prescribe, the public is placed at serious risk of potentially dangerous side effects, drug interactions, and contraindications,” said Vanessa R. Waldref, United States Attorney for the Eastern District of Washington.  “This resolution demonstrates our strong commitment to protecting public health and to keeping our communities strong and safe. In particular, I commend the excellent investigative work conducted by DEA’s Diversion Group, and the Department of Health and Human Services Office of Inspector General.  We will continue to work with our law enforcement partners to hold health care practitioners accountable.”

These are the latest in a series of settlements the U.S. Attorney’s Office has announced with naturopaths for improperly prescribing controlled substances.  In November 2021, Dr. Christopher M. Valley, a Spokane-based naturopath, agreed to pay $47,700 to resolve his liability under the Controlled Substances Act, while Dr. Judith Caporiccio, a Richland naturopath, entered into a $70,096 settlement resolving her liability in February 2022. 

The settlement was the result of a joint investigation conducted by DEA’s Seattle Field Office, Diversion Group, the U.S. Department of Health and Human Services, Office of Inspector General, Seattle Field Office, and the U.S. Attorney’s Office for the Eastern District of Washington.  Assistant United States Attorneys Dan Fruchter and Tyler H.L. Tornabene handled this matter on behalf of the United States.

###

Opioids
  • Facebook
  • Twitter
  • Email

SAMHSA Behavioral Health Treatment Locator

  • Quienes Somos
    • Sobre
    • Divisiones Nacionales
    • Oficinas Extranjeras
    • Contáctenos
    • Museo DEA
  • Lo Que Hacemos
    • Prevención de Drogas
    • Aplicacion de la Ley
    • División de Control de Desvío
    • Noticias
  • Carreras
    • Resumen
    • Agente Especial
    • Investigador de Desvío
    • Especialista en Investigación de Inteligencia
  • Recursos
    • Información sobre las Drogas
    • Programa de Asistencia al Empleado
    • Empleador con Igualdad de Oportunidades
    • Ley de Libertad de Información (FOIA)
    • Publicaciones
    • Galerías Multimedia
    • Programa de Asistencia a Testigos para Víctimas
  • Hacer Negocios
    con la DEA
    • Resumen
    • Proveedores Actuales
    • Futuros Vendedores
    • Cláusulas de Seguridad
    • Formularios de Seguridad
    • Programa de Pequeñas Empresas
  • Políticas
    • Accesibilidad, Complementos y Política
    • Políticas Legales y Descargos de Responsabilidad
    • Antidiscriminación y Represalias Acto
    • Política de Privacidad
    • Política de Igualdad de Oportunidades en el Empleo del U.S. DOJ
    • USA.gov
    • Protección de Denunciantes
Inicio

United States Drug Enforcement Administration

DEA.gov is an official site of the U.S. Department of Justice
Facebook Twitter LinkedIn Instagram

DEA Contact Center

(202) 307-1000 info@dea.gov
Contact the Webmaster